Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polaprezinc quadruple therapy versus bismuth quadruple therapy for Helicobacter pylori eradication
ChiCTR1900025800Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Sep 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of polaprezinc and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Helicobacter pylori eradication rate. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
polaprezincbismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR1900025800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025800.